ADAP Stock Adaptimmune Therapeutics (ADAP, $0.06) Aroon Indicator entered a Downtrend on August 29, 2025.
at Tickeron.com
ADAP's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ADAP turned positive on August 19, 2025. Looking at past instances where ADAP's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ADAP's RSI Indicator exited the oversold zone, of 45 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ADAP advanced for three days, in of 220 cases, the price rose further within the following month. The odds of a continued upward trend are .
ADAP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADAP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ADAP entered a downward trend on August 29, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.921) is normal, around the industry mean (19.994). P/E Ratio (0.000) is within average values for comparable stocks, (51.700). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.073). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (0.163) is also within normal values, averaging (325.279).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ADAP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADAP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Advertisement
General Information
a manufacturer of vaccines and cancer immunotherapy products
Industry Biotechnology